TC99M-NEOGALACTOALBUMIN EVALUATION OF LIVER DISEASE
TC99M-NEOGALACTOALBUMIN EVALUATION OF LIVER DISEASE
批准号:
3232965
负责人:
ROBERT CHARLES STADALNIK
金额:
$20.05万
依托单位国家:
美国
项目类别:
财政年份:
1984
资助国家:
美国
项目状态:
已结题
起止时间:
1984-12-01 至 1989-11-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
We propose to continue to prospectively obtain comparisons of Tc-NGA
estimates of hepatic functional capacity with quantitative functional
values obtained from the 14C-aminopyrine breath test (ABT) to define the
severity of liver disease. The ABT test has been found useful to assess
liver function and provide a simple procedure for the quantitative
assessment of microsomal and hepatocyte function in man. The test is more
sensitive in detecting hepatocellular disease than standard liver function
tests. The ABT is easy to perform, is non-invasive and will serve as a
complement to other liver function tests. The ABT score is a reliable
measure of histologic liver damage in viral hepatitis, severe hepatic
necrosis from any cause, drug or viral, and in alcoholic liver disease. It
also correlates well with histopathologic improvement in those conditions.
Based on estimates of HBP concentration, Tc-NGA functional liver imaging
should be of particular prognostic importance in diseases such as hepatic
necrosis, chronic hepatitis and candidates for liver transplantation. It
may serve a role in evaluating major medical or surgical therapies such as
corticosteroid treatment and portal systemic shunting. We plan to examine
the usefulness of Tc-NGA as a quantitative liver function test in three
areas: 1) Determination of prognosis, 2) Evaluation of medical and
surgical therapies, 3) Liver blood flow.
All patients will have endogenous ligand assay from a serum sample.
Various investigators have reported increased levels of circulating
asialoglycoprotein in patients with liver disease. These values, however,
are two orders of magnitude below our estimates of normal receptor
concentration. Severe cirrhosis may depress [R] such that endogenous
ligand may influence our receptor estimates. These values will be compared
to the receptor estimates obtained from kinetic analysis. Although we have
validated (see Progress Report) the in vivo receptor estimates using
healthy pigs, correlation of in vitro and in vivo measurements in human
disease will significantly contribute to the validation of Tc-NGA as a
functional imaging agent for in vivo biochemistry. When possible we will
also retrieve and assay liver biopsy samples for HBP concentration.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TC-99M NGA IN THE EVALUATION OF LIVER DISEASE
-
批准号:3232960
-
项目类别:
-
资助金额:$22.64万
-
财政年份:1984
-
负责人:ROBERT CHARLES STADALNIK
-
依托单位:
TC-99M NGA IN THE EVALUATION OF LIVER DISEASE
-
批准号:3232961
-
项目类别:
-
资助金额:$24.81万
-
财政年份:1984
-
负责人:ROBERT CHARLES STADALNIK
-
依托单位:
TC-99M NGA IN THE EVALUATION OF LIVER DISEASE
-
批准号:3232964
-
项目类别:
-
资助金额:$19.53万
-
财政年份:1984
-
负责人:ROBERT CHARLES STADALNIK
-
依托单位:
TC-99M NGA IN THE EVALUATION OF LIVER DISEASE
-
批准号:3232966
-
项目类别:
-
资助金额:$26.87万
-
财政年份:1984
-
负责人:ROBERT CHARLES STADALNIK
-
依托单位:
TC-99M NGA IN THE EVALUATION OF LIVER DISEASE
-
批准号:3232967
-
项目类别:
-
资助金额:$28.38万
-
财政年份:1984
-
负责人:ROBERT CHARLES STADALNIK
-
依托单位:
TC99M-NEOGALACTOALBUMIN EVALUATION OF LIVER DISEASE
-
批准号:3153320
-
项目类别:
-
资助金额:$12.86万
-
财政年份:1984
-
负责人:ROBERT CHARLES STADALNIK
-
依托单位:
TC99M-NEOGALACTOALBUMIN EVALUATION OF LIVER DISEASE
-
批准号:3232963
-
项目类别:
-
资助金额:$11.99万
-
财政年份:1984
-
负责人:ROBERT CHARLES STADALNIK
-
依托单位:
海外基金